JonesTrading analyst Catherine Novack has maintained their neutral stance on KRRO stock, giving a Hold rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Catherine Novack’s rating is based on several factors impacting Korro Bio’s current and future prospects. The company’s recent announcement revealed that their KRRO-110 treatment did not achieve the desired functional AAT levels in AATD patients, leading to a decision to halt further clinical development of this candidate. This setback, coupled with the absence of immediate catalysts and the failure to establish proof-of-concept for their RNA editing platform, has contributed to the Hold rating.
Despite these challenges, Korro Bio is redirecting its focus towards a new delivery method, GalNAc, with plans to nominate a development candidate by the first half of 2026. Additionally, they are preparing to initiate a Phase 1 trial for another RNA editing candidate, KRRO-121, in the second half of 2026. The company’s financial position, with a cash reserve of $102.5 million as of the third quarter of 2025 and a workforce reduction extending their financial runway into the second half of 2027, provides some stability. However, the lack of near-term developments and the uncertainty surrounding their new strategic direction justify the Hold recommendation.